There is some support that remembered parenting styles continue to be related to functioning across the lifespan. There is also evidence of resiliency, flexibility, and malleability in human development.

The National Institute on Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical Trials Network (CTN) to conduct trials of promising substance abuse treatment interventions in diverse clinical settings and to disseminate results of these trials. This paper focuses on three dimensions of the CTN’s organizational functioning. First, a longitudinal dataset is used to examine the CTN’s formation as a network of inter-organizational interaction among treatment practitioners and researchers. Data indicate strong relationships of interaction and trust, but a decline in problem-centered inter-organizational interaction over time. Second, adoption of buprenorphine and motivational incentives among the CTN’s affiliated CTPs is identified over three waves of data. While adoption is found to increase with CTPs’ CTN participation, there is only modest evidence of widespread penetration and implementation. Third, CTPs’ pursuit of the CTN’s dissemination goals are examined, indicating that such organizational outreach activities are underway and likely to increase innovation diffusion in the future.

Given that parenthood is considered a central adult status with developmental implications, and an increasing number of adults are childless, we assessed whether adult development is structured differently for parents and non-parents. This study's main goal was to assess and compare the connection between generativity development-a key task of middle adulthood-and psychological well-being for childless adults (N = 289) and parents (N = 2,218), ages 35-74, using the 1995 MIDUS dataset. We also examined differences in these associations for women and men by parental status, because childlessness is often assumed to be more critical for females' than males' development. Structural equation modeling indicated a positive association between generativity and psychological well-being. Differences in this association for parents and childless adults were not evident, nor were there significant differences for childless women and mothers, and childless men and fathers. Implications of these findings are discussed.

Organizational participation in clinical research may lead to adoption of the intervention by treatment agencies, but it is not known whether research involvement enhances innovativeness beyond the specific interventions that are tested. The National Institute on Drug Abuse's (NIDA) Clinical Trial Network (CTN) is a platform for considering this research question. To date, the CTN has not conducted research on medications for alcohol use disorders (AUDs), so greater adoption of innovative AUD pharmacotherapies by CTN-affiliated programs would suggest an added value of research network participation. Using longitudinal data from a pooled sample of CTN and non-CTN publicly funded treatment programs, we investigate adoption of tablet naltrexone and acamprosate over a two-year period. CTN-affiliated programs were more likely to have adopted tablet naltrexone and acamprosate at 24-month follow-up, net of the effects of a range of organizational characteristics. Research network participation may thus enhance organizational innovativeness to include interventions beyond the scope of the network.

This study assessed counselors’ knowledge of the adoption of evidence-based tobacco cessation medications (TCMs) - varenicline, bupropion, and five nicotine replacement therapies (NRTs) - and predictors of adoption in diverse substance abuse treatment settings. We used MERITS I data from 658 counselors working in 26 programs. Adoption of varenicline was reported by 16% of counselors, bupropion by 11%, and NRTs by 27%. Knowledge of the adoption of all types of TCMs was more likely to be reported by counselors who worked in treatment programs that adhered less to a 12-step orientation and restricted outdoor smoking for employees. Several additional unique predictors of varenicline and NRTs were identified.